In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 30, No. 15_suppl ( 2012-05-20), p. e21072-e21072
Abstract:
e21072 Background: We previously reported that in mice, 18 F-FDG uptake is higher in hypoxic cancer cells than well-oxygenated xenografts of human cancer cells. This enhanced uptake was abrogated by carbogen (95% O2 +5% CO2) breathing. We hypothesized that in clinical applications, oxygen breathing of the patients’ during the uptake phase may blunt the 18 F-FDG uptake of the tumor and the liver. Methods: Overnight fasted patients with blood glucose level 〈 200 mg/dl were injected with 〈 14.0 mCi of 18 F-FDG, and PET/CT scans were performed at 60 -80 minutes later with a Siemens PET/CT scanner. Group-1 is consisted of 11 patients who were breathing room air only, without any additional oxygen during the procedure. Group-II consisted of 12 patients who were breathing oxygen during the uptake phase. Group-III consisted of 10 patients who were breathing oxygen only at the time of scanning and not during uptake phase. Tumor FDG activities of the groups were not compared since no paired data (with and without oxygen in same patient) was available. Thus, Liver FDG activity of the patients in each group were measured as surrogate to the oxygen effect on tumor, and expressed as Liver SUV max and Liver SUV average values, and they were compared to each other to determine the statistical significance. Results: Both liver SUV max and SUV average values were significantly lower in Group-II patients who were breathing oxygen during the uptake phase compared to Group–I and Group-III (P 〈 0.05 for both). Liver SUV max and SUV average values were not significantly different between Group–I and Group–III. In one patient who had a paired scans with and without O 2 during the uptake phase showed a significant FDG activity of the tumor when he was breathing O 2 during uptake phase. Conclusions: In cancer patients, O 2 breathing during FDG uptake phase may significantly blunt 18 F-FDG uptake, thus, in cancer patients this may decrease the accuracy of the FDG PET/CT for the detection, staging of the disease and the assessment of the therapy effect. [Table: see text]
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2012.30.15_suppl.e21072
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2012
detail.hit.zdb_id:
2005181-5
Permalink